巴瑞替尼对类风湿关节炎小鼠模型血脑屏障薄弱区小胶质细胞及STAT3的抑制作用
该研究在胶原诱导性关节炎(CIA)小鼠模型中,于免疫后第35天(早期)和第84天(晚期)比较巴瑞替尼与溶媒对照对最后区小胶质细胞及STAT3的影响。早期巴瑞替尼减少最后区活化小胶质细胞、抑制磷酸化STAT3并恢复摄食与蔗糖偏好,晚期对小胶质细胞形态无影响。作者认为巴瑞替尼可作用于血脑屏障薄弱区脑细胞并减轻自身免疫性关节炎中的异常行为。
要点
- 早期巴瑞替尼减少CIA小鼠最后区活化小胶质细胞并抑制磷酸化STAT3。
- 早期巴瑞替尼伴随摄食与蔗糖偏好恢复,晚期对最后区小胶质细胞形态无影响。
- 作者指出结果提示JAK抑制剂对RA相关脑病理的潜在治疗作用。
核心结论
- 作者认为巴瑞替尼可作用于血脑屏障薄弱区的脑细胞(尤其小胶质细胞),并减轻自身免疫性关节炎期间的异常行为,提示JAK抑制剂对RA相关脑病理的潜在治疗作用。
研究设计与样本
- 采用胶原诱导性关节炎(CIA)小鼠模型,比较巴瑞替尼组与溶媒对照组,于免疫后第35天(早期)和第84天(晚期)采集数据。
- 以离子钙接头分子-1(Iba-1)免疫染色评估最后区小胶质细胞数量与形态,并以免疫组化检查最后区STAT3。
- 通过摄食行为和蔗糖偏好测试评估行为学结局。
主要发现
- 早期阶段,巴瑞替尼组最后区活化小胶质细胞水平较溶媒对照组降低,并伴随磷酸化STAT3抑制及摄食与蔗糖偏好恢复。
- 晚期阶段,巴瑞替尼对最后区小胶质细胞形态无影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In patients with RA, baricitinib not only improves arthritis symptom severity, but also patients' neuropsychological symptoms, such as depression and fatigue. However, the cellular mechanisms through which baricitinib can affect neural activity is unexplored. While the blood-brain barrier (BBB) permeability of this drug remains unclear, Janus kinase inhibitors (JAKi) might reach the area postrema, which is a unique brain region with a weak BBB function. Our recent study demonstrated microglial activation during experimental arthritis in the area postrema. Therefore, we sought to assess the effect of baricitinib on microglia in the area postrema using the CIA mouse model. METHODS: Microglia number and morphology in the area postrema were assessed by immunostaining for ionized calcium-binding adaptor molecule-1 (Iba-1). Data were collected on post-immunization day 35 (early phase) and 84 (late phase), and compared between baricitinib- and vehicle-treated mice. The effect on signal transducers and activators of transcription (STAT3) in the area postrema was also immunohistochemically examined. Behavioural outcomes were assessed by examining feeding behaviours and sucrose preference tests. RESULTS: In the early phase, activated microglial levels in the area postrema were decreased by baricitinib, accompanied by the inhibition of phosphorylated-STAT3 and recovery of food intake and sucrose preference. On the other hand, baricitinib did not affect microglial morphology in the late phase. CONCLUSION: Our results demonstrate that baricitinib can affect brain cells, specifically microglia, in the brain region with a weak BBB and mitigate aberrant behaviours during autoimmune arthritis, pointing to the potential therapeutic effect of JAKi on brain pathologies underpinning RA.
引用
- Matsushita T, Otani K, Yoshiga M, et al. Inhibitory effect of baricitinib on microglia and STAT3 in a region with a weak blood-brain barrier in a mouse model of rheumatoid arthritis. Rheumatology (Oxford). 2023. PMID: 36648313. doi:10.1093/rheumatology/kead013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。